Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

Final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study

Michele Baccarani, Brian Druker, Susan Branford, Dong Wook Kim, Fabrizio Pane, Lidia Mongay, Manisha Mone, Christine Elke Ortmann, Hagop M. Kantarjian, Jerald P. Radich, Timothy P. Hughes, Jorge E. Cortes, François Guilhot

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The TOPS trial evaluated high- (800 mg/day; n = 319) versus standard-dose (400 mg/day; n = 157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Patients had a minimum follow-up of 42 months or discontinued early. Major molecular response (MMR) rates were similar between arms at (51.6 vs 50.2 % for 400 and 800 mg/day, respectively; P = 0.77) and by (75.8 vs 79.0 %; P = 0.4807) 42 months. There were no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (OS) between arms. The estimated rates of PFS on treatment and OS at 42 months were significantly higher in patients with MMR at 6, 12, and 18 months compared with those without MMR. Adverse events were more frequent with high-dose imatinib. Patients with ≤1 treatment interruption (vs >1) and those able to maintain imatinib ≥600 mg/day (vs

Original languageEnglish (US)
Pages (from-to)616-624
Number of pages9
JournalInternational Journal of Hematology
Volume99
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Leukemia, Myeloid, Chronic Phase
Philadelphia Chromosome
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Disease-Free Survival
Survival
TOPS
Imatinib Mesylate
Therapeutics

Keywords

  • BCR-ABL
  • Chronic myeloid leukemia
  • Imatinib
  • Phase 3 clinical trial
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase : Final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. / Baccarani, Michele; Druker, Brian; Branford, Susan; Kim, Dong Wook; Pane, Fabrizio; Mongay, Lidia; Mone, Manisha; Ortmann, Christine Elke; Kantarjian, Hagop M.; Radich, Jerald P.; Hughes, Timothy P.; Cortes, Jorge E.; Guilhot, François.

In: International Journal of Hematology, Vol. 99, No. 5, 2014, p. 616-624.

Research output: Contribution to journalArticle

Baccarani, Michele ; Druker, Brian ; Branford, Susan ; Kim, Dong Wook ; Pane, Fabrizio ; Mongay, Lidia ; Mone, Manisha ; Ortmann, Christine Elke ; Kantarjian, Hagop M. ; Radich, Jerald P. ; Hughes, Timothy P. ; Cortes, Jorge E. ; Guilhot, François. / Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase : Final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. In: International Journal of Hematology. 2014 ; Vol. 99, No. 5. pp. 616-624.
@article{8687e1fc12384764a5bef61d222c2de6,
title = "Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: Final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study",
abstract = "The TOPS trial evaluated high- (800 mg/day; n = 319) versus standard-dose (400 mg/day; n = 157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Patients had a minimum follow-up of 42 months or discontinued early. Major molecular response (MMR) rates were similar between arms at (51.6 vs 50.2 {\%} for 400 and 800 mg/day, respectively; P = 0.77) and by (75.8 vs 79.0 {\%}; P = 0.4807) 42 months. There were no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (OS) between arms. The estimated rates of PFS on treatment and OS at 42 months were significantly higher in patients with MMR at 6, 12, and 18 months compared with those without MMR. Adverse events were more frequent with high-dose imatinib. Patients with ≤1 treatment interruption (vs >1) and those able to maintain imatinib ≥600 mg/day (vs",
keywords = "BCR-ABL, Chronic myeloid leukemia, Imatinib, Phase 3 clinical trial, Tyrosine kinase inhibitor",
author = "Michele Baccarani and Brian Druker and Susan Branford and Kim, {Dong Wook} and Fabrizio Pane and Lidia Mongay and Manisha Mone and Ortmann, {Christine Elke} and Kantarjian, {Hagop M.} and Radich, {Jerald P.} and Hughes, {Timothy P.} and Cortes, {Jorge E.} and Fran{\cc}ois Guilhot",
year = "2014",
doi = "10.1007/s12185-014-1566-2",
language = "English (US)",
volume = "99",
pages = "616--624",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

T2 - Final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study

AU - Baccarani, Michele

AU - Druker, Brian

AU - Branford, Susan

AU - Kim, Dong Wook

AU - Pane, Fabrizio

AU - Mongay, Lidia

AU - Mone, Manisha

AU - Ortmann, Christine Elke

AU - Kantarjian, Hagop M.

AU - Radich, Jerald P.

AU - Hughes, Timothy P.

AU - Cortes, Jorge E.

AU - Guilhot, François

PY - 2014

Y1 - 2014

N2 - The TOPS trial evaluated high- (800 mg/day; n = 319) versus standard-dose (400 mg/day; n = 157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Patients had a minimum follow-up of 42 months or discontinued early. Major molecular response (MMR) rates were similar between arms at (51.6 vs 50.2 % for 400 and 800 mg/day, respectively; P = 0.77) and by (75.8 vs 79.0 %; P = 0.4807) 42 months. There were no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (OS) between arms. The estimated rates of PFS on treatment and OS at 42 months were significantly higher in patients with MMR at 6, 12, and 18 months compared with those without MMR. Adverse events were more frequent with high-dose imatinib. Patients with ≤1 treatment interruption (vs >1) and those able to maintain imatinib ≥600 mg/day (vs

AB - The TOPS trial evaluated high- (800 mg/day; n = 319) versus standard-dose (400 mg/day; n = 157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Patients had a minimum follow-up of 42 months or discontinued early. Major molecular response (MMR) rates were similar between arms at (51.6 vs 50.2 % for 400 and 800 mg/day, respectively; P = 0.77) and by (75.8 vs 79.0 %; P = 0.4807) 42 months. There were no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (OS) between arms. The estimated rates of PFS on treatment and OS at 42 months were significantly higher in patients with MMR at 6, 12, and 18 months compared with those without MMR. Adverse events were more frequent with high-dose imatinib. Patients with ≤1 treatment interruption (vs >1) and those able to maintain imatinib ≥600 mg/day (vs

KW - BCR-ABL

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Phase 3 clinical trial

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84901601715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901601715&partnerID=8YFLogxK

U2 - 10.1007/s12185-014-1566-2

DO - 10.1007/s12185-014-1566-2

M3 - Article

VL - 99

SP - 616

EP - 624

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -